texte alternatif                                    

    List of publications of Mattia Rediti


      Peer-reviewed journal articles (14)
  1. 1. Rediti, M., Fimereli, D., Mileva, M., Wimana, Z., Venet, D., Flamen, P., Guiot, T., de Vries, E. E., Schröder, C. P., Menke-van der Houven van Oordt, W. C., Maetens, M. M., Majjaj, S., Larsimont, D., Rothé, F., Sotiriou, C., & Gebhart, G. (2025). Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial. Clinical cancer research, 31(1), 110-121. doi:10.1158/1078-0432.CCR-24-1007
  2. 2. Fernandez-Martinez, A., Tanioka, M., Ahn, S. G., Zagami, P., Pascual, T., Rediti, M., Tang, G., Hoadley, K. A., Venet, D., Rashid, N. U., Spears, P. A., Di Cosimo, S., de Azambuja, E., Choudhury, A., Rastogi, P., Islam, M. N., Cortes, J., Llombart-Cussac, A., Swain, S. M., Sotiriou, C., Prat, A., Perou, C. M., & Carey, L. A. (2024). Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC). Annals of oncology. doi:10.1016/j.annonc.2024.12.010
  3. 3. Rediti, M., Venet, D., Joaquin Garcia, A., Maetens, M. M., Vincent, D., Majjaj, S., El-abed, S., Di Cosimo, S., Ueno, T., Izquierdo, M., Piccart-Gebhart, M., Pusztai, L., Loi, S., Salgado, R., Viale, G., Rothé, F., & Sotiriou, C. (2024). Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial. Nature communications, 15(1), 10402. doi:10.1038/s41467-024-54621-3
  4. 4. Wang, X., Venet, D., Lifrange, F., Larsimont, D., Rediti, M., Stenbeck, L., Dupont, F., Rouas, G., Garcia, A. J., Craciun, L., Buisseret, L., Ignatiadis, M., Carausu, M., Bhalla, N., Masarapu, Y., Villacampa, E. G., Franzén, L., Saarenpää, S., Kvastad, L., Thrane, K., Lundeberg, J., Rothé, F., & Sotiriou, C. (2024). Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications. Nature communications, 15(1), 10232. doi:10.1038/s41467-024-54145-w
  5. 5. Fernandez-Martinez, A., Rediti, M., Tang, G., Pascual, T., Hoadley, K. K., Venet, D., Rashid, N. N., Spears, P. P., Islam, M. N., El-abed, S., Bliss, J. M., Lambertini, M. M. P. M., Di Cosimo, S., Huobe, J., Goerlitz, D., Hu, R., Lucas, P. P., Swain, S. S., Sotiriou, C., Perou, C. C., & Carey, L. L. (2024). Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2 -Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials. JAMA oncology. doi:10.1001/jamaoncol.2023.7304
  6. 6. Rediti, M., Fernandez-Martinez, A., Venet, D., Rothé, F., Hoadley, K. A., Parker, J. S., Singh, B., Campbell, J. D., Ballman, K. V., Hillman, D. W., Winer, E. P., El-Abed, S., Piccart, M., Di Cosimo, S., Symmans, W. F., Krop, I., Salgado, R., Loi, S., Pusztai, L., Perou, C. M., Carey, L. A., & Sotiriou, C. (2023). Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nature communications, 14(1), 7053. doi:10.1038/s41467-023-42635-2
  7. 7. Joaquin Garcia, A., Rediti, M., Venet, D., Majjaj, S., Kammler, R., Munzone, E., Gianni, L., Thürlimann, B., Láng, I., Colleoni, M. A., Loi, S., Viale, G., Regan, M. M., Buisseret, L., Rothé, F., & Sotiriou, C. (2023). Differential benefit of metronomic chemotherapy among triple negative breast cancer subtypes treated in the IBCSG Trial 22-00. Clinical cancer research. doi:10.1158/1078-0432.CCR-23-1267
  8. 8. Wang, X.-M., Collet, L., Rediti, M., Debien, V., De Caluwé, A., Venet, D., Romano, E., Rothé, F., Sotiriou, C., & Buisseret, L. (2023). Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges. Journal of Clinical Medicine, 12(3). doi:10.3390/jcm12030953
  9. 9. Fimereli, D., Venet, D., Rediti, M., Boeckx, B., Maetens, M., Majjaj, S., Rouas, G., Marchio, C., Bertucci, F., Mariani, O., Capra, M., Bonizzi, G., Contaldo, F., Galant, C., Van den Eynden, G., Salgado, R., Biganzoli, E., Vincent-Salomon, A., Pruneri, G., Larsimont, D., Lambrechts, D., Desmedt, C., Brown, D. N., Rothé, F., & Sotiriou, C. (2022). Timing evolution of lobular breast cancer through phylogenetic analysis. EBioMedicine, 82, 104169. doi:10.1016/j.ebiom.2022.104169
  10. 10. Rothé, F., Venet, D., Peeters, D., Rouas, G., Rediti, M., Smeets, D., Dupont, F., Campbell, P., Lambrechts, D., Dirix, L. Y., Sotiriou, C., & Ignatiadis, M. (2022). Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis. NPJ breast cancer, 8(1), 79. doi:10.1038/s41523-022-00445-7
  11. 11. Venet, D., Rediti, M., Maetens, M. M., Fumagalli, D., Brown, D. N., Majjaj, S., Salgado, R., Pusztai, L., Harbeck, N., El-Abed, S., Wang, Y., Saura, C., Gomez, H., Semiglazov, V. F., de Azambuja, E., Huober, J., Nuciforo, P. G., Di Cosimo, S., Piccart-Gebhart, M., Loi, S., Rothé, F., & Sotiriou, C. (2021). Copy number aberration analysis to predict response to neoadjuvant antiHER2 therapy: results from the NeoALTTO phase III clinical trial. Clinical cancer research, 27(20), 5607-5618. doi:10.1158/1078-0432.CCR-21-1317
  12. 12. Agostinetto, E., Rediti, M., Fimereli, D., Debien, V., Piccart, M., Aftimos, P., Sotiriou, C., & de Azambuja, E. (2021). HER2-Low Breast Cancer: Molecular Characteristics and Prognosis. Cancers (Basel), 13(11). doi:10.3390/cancers13112824
    13. << Previous 1 2 Next >>